Finally, ladarixin is evaluated in novel phase II/III studies in which the efficacy of this CXCR1/CXCR2 antagonist in longer-term therapy of type 1 diabetes will be assessed, after no effect was seen with short-term treatment only (Table 3) [188]. This evidence concerns the gene CXCR2 and type 1 diabetes mellitus.